Universität zu Köln

Zhou, Qi, Liu, Zhenxing, Xu, Guotong, Bock, Felix, Cursiefen, Claus, Sui, Guiqin and Bi, Yanlong (2016). Regression of mature corneal lymphatic vessels by intracorneal ranibizumab injection. Int. J. Clin. Exp. Med., 9 (3). S. 5932 - 5942. MADISON: E-CENTURY PUBLISHING CORP. ISSN 1940-5901

Full text not available from this repository.

Abstract

Objective: Ranibizumab is a Fab fragment of a recombinant, humanized, monoclonal anti-vascular endothelial growth factor (VEGF) antibody. This study analyzes the possibility of regressing lymphangiogenesis and hemangiogenesis by intracorneal ranibizumab injection. In addition, the effect of ranibizumab on corneal endothelial cells (CECs) of mice is also studied. Methods: Hemangiogenesis and lymphangiogenesis were induced in female BALB/c mice using the murine model of suture-induced inflammatory neovascularisation. The treatment group received an intracorneal injection of ranibizumab (controls: phosphate buffered saline (PBS)). Corneas were excised at different time points (1 day, 5 days, and 10 days) after the injection, and corneal whole mounts were stained with CD31, LYVE-1, and alizarin red S to quantify hemangiogenesis, lymphangiogenesis, and corneal endothelium. The morphology was analyzed by using the image analysing programme Cell boolean AND F and Image J image analysis programme, respectively. Results: In accordance with our previous findings, lymphatic vessels and blood vessels could be reduced after an intracorneal ranibizumab injection: One day after the injection, lymphatic vessels were reduced by 18% (P = 0.4), blood vessels were reduced by 22% (P = 0.083); after 5 days and 10 days, lymphatic vessels were reduced by 50% (P = 0.002) and 63% (P < 0.001), respectively, and blood vessels were reduced by 52% (P = 0.0031) and 68% (P < 0.001), respectively. The corneal endothelial morphology showed no significant differences after the intracorneal ranibizumab injection for 10 days (all P > 0.05). Conclusions: This study is the first to demonstrate that the intracorneal ranibizumab injection is a novel technique to specifically induce regression of corneal lymphatics and blood vessels without affecting corneal endothelial cells.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Zhou, Qi UNSPECIFIED UNSPECIFIED UNSPECIFIED Liu, Zhenxing UNSPECIFIED UNSPECIFIED UNSPECIFIED Xu, Guotong UNSPECIFIED UNSPECIFIED UNSPECIFIED Bock, Felix UNSPECIFIED UNSPECIFIED UNSPECIFIED Cursiefen, Claus UNSPECIFIED UNSPECIFIED UNSPECIFIED Sui, Guiqin UNSPECIFIED UNSPECIFIED UNSPECIFIED Bi, Yanlong UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-289777
Journal or Publication Title:	Int. J. Clin. Exp. Med.
Volume:	9
Number:	3
Page Range:	S. 5932 - 5942
Date:	2016
Publisher:	E-CENTURY PUBLISHING CORP
Place of Publication:	MADISON
ISSN:	1940-5901
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS; NEOVASCULARIZATION; BEVACIZUMAB; ANGIOGENESIS; SUBCONJUNCTIVAL; LYMPHANGIOGENESIS; VERTEPORFIN Multiple languages Medicine, Research & Experimental Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/28977